Glaxosmithkline Plc (GSK) 45.15 $GSK These Biotech's are

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Glaxosmithkline Plc (GSK) 45.15 $GSK

These Biotech's are Due for a Run
ACCESSWIRE - 2 hrs 10 mins ago
It's an Interesting Time in the Biotech Market, and with Labor Day on the Horizon, here's a few Biotechs that could Bring You Closer to Financial Independence
ACRX: 3.56 (-0.20), GSK: 45.15 (+0.12)

Global Adult Vaccines Company Analysis and Forecast 2007-2021 - Research and Markets
PR Newswire Europe - Thu Aug 04, 11:10AM CDT
Research and Markets has announced the addition of the "Global - Adult Vaccines Market - Company Analysis and Forecast to 2021" [http://www.researchandmarkets.com/research/fvbppv/global_adult] report to their offering.
MRK: 57.92 (+0.27), GSK: 45.15 (+0.12), NVS: 82.91 (+0.51)

Ionis Pharmaceuticals (IONS) Q2 Earnings: Stock to Beat?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:08AM CDT
Ionis (IONS) is scheduled to report second-quarter 2016 results on Aug 9.
IPXL: 31.30 (-0.32), BIIB: 315.53 (-5.81), GSK: 45.15 (+0.12), IONS: 37.07 (-0.66)

ADAP: a Biotech Stock Using T-Cell Immunotherapy to Treat Cancer
Maher Syed - Zacks Investment Research - Mon Aug 01, 5:13PM CDT
Here's why Adaptimmune therapeutics looks like an intriguing investment prospect right now.
ADAP: 8.58 (-0.20), GSK: 45.15 (+0.12)

Karuna Pharmaceuticals Appoints Atul Pande, M.D., to Board of Directors
BusinessWire - Fri Jul 29, 9:00AM CDT
Karuna Pharmaceuticals, a company focused on targeting muscarinic receptors for the treatment of central nervous system disorders, today announced the appointment of Atul Pande, M.D., to its Board of Directors. Dr. Pande brings to Karuna more than 25 years of experience in the fields of psychiatry and neurosciences and an expertise in drug development.
AXON: 15.53 (+0.04), GSK: 45.15 (+0.12)

M Pharmaceutical Inc. Announces New U.S. Operating Company Located in Greater Cincinnati
Filing Services Canada XHTML - Fri Jul 29, 12:01AM CDT

GSK: 45.15 (+0.12)

Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Glaxo (GSK) reported second-quarter 2016 core earnings of 70 cents per American depositary share, beating the Zacks Consensus Estimate of 55 cents.
INVA: 12.83 (-0.18), ANIP: 66.70 (+4.60), GSK: 45.15 (+0.12), NVS: 82.91 (+0.51)

Watch for GlaxoSmithKline to Potentially Pullback After Gaining 1.59% Yesterday
Comtex SmarTrend(R) - Wed Jul 27, 1:03PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $44.79 to a high of $45.13. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $44.41 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)

SmarTrend Watching for Potential Pullback in Shares of GlaxoSmithKline After 1.59% Gain
Comtex SmarTrend(R) - Wed Jul 27, 1:01PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $44.79 to a high of $45.13. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $44.41 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)

Novartis (NVS) Likely to Beat Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 11:10AM CDT
Novartis AG (NVS) is scheduled to report second-quarter 2016 results on Jul 19.
JNJ: 123.87 (-0.03), GILD: 79.78 (-0.31), GSK: 45.15 (+0.12), NVS: 82.91 (+0.51)

Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 34.34 (+0.25), LLY: 82.45 (-0.27), GSK: 45.15 (+0.12), BMY: 75.57 (+0.77)

Mylan Launches Generic Avodart® Capsules
PR Newswire - Fri Jun 24, 10:44AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
MYL: 48.84 (+0.43), GSK: 45.15 (+0.12)

AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 123.87 (-0.03), PFE: 35.27 (-0.02), AZN: 34.34 (+0.25), GSK: 45.15 (+0.12)

New Stock Research Reports for June 21, 2016
Sheraz Mian - Zacks Investment Research - Tue Jun 21, 1:44PM CDT
New Stock Research Reports for June 21, 2016
FB: 124.39 (+1.88), DD: 68.82 (-0.09), CAT: 81.79 (-0.24), GSK: 45.15 (+0.12), INTC: 34.55 (+0.30), PEP: 108.14 (+0.10)

Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Glaxo (GSK) and Innoviva (INVA) announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy for the treatment of COPD.
INVA: 12.83 (-0.18), TBPH: 24.37 (-0.25), GSK: 45.15 (+0.12), BMY: 75.57 (+0.77)

Look for Shares of GlaxoSmithKline to Potentially Pullback after Yesterday's 3.24% Rise
Comtex SmarTrend(R) - Mon Jun 20, 2:15PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)

SmarTrend Watching for Potential Pullback in Shares of GlaxoSmithKline After 3.24% Gain
Comtex SmarTrend(R) - Mon Jun 20, 2:13PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)

February 2017 Options Now Available For GlaxoSmithKline (GSK)
DividendChannel.com - Mon Jun 20, 10:01AM CDT
Investors in GlaxoSmithKline plc saw new options begin trading today, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the...
GSK: 45.15 (+0.12)

Watch for GlaxoSmithKline to Potentially Rebound After Falling 2.13% Yesterday
Comtex SmarTrend(R) - Tue Jun 14, 1:10PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $39.76 to a high of $40.40. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $40.77 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 45.15 (+0.12)

Milner Therapeutics Institute Announces New Partnership With Japanese Pharmaceutical Company Shionogi
PR Newswire Europe - Mon Jun 13, 4:51AM CDT
CAMBRIDGE, England, June 13, 2016 /PRNewswire/ --
GSK: 45.15 (+0.12)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 65

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 29

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 65

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 53

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 164

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 40

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 59

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading

Top 5 Most Recently Viewed Articles

Concentrix Unveils Ambitious Sustainability Goals for 2025

Updated Category News Views 366

Concentrix Releases Significant Sustainability Report Concentrix Corporation (NASDAQ: CNXC), a leader in global technology and services, recently revealed its 2025 Sustainability Report titled ‘The Power of One’. This comprehensive document showcases the company’s commitment to achieving its 2030 environmental, social, and governance (ESG) goals. These objectives...

Continue Reading
Hingham Institution for Savings Achieves Remarkable Q3 Growth

Updated Category News Views 193

Summary of Third Quarter Financial Results Hingham Institution for Savings (NASDAQ: HIFS) recently announced its financial results for the quarter ending September 30, 2025, reflecting a significant leap in profitability and growth metrics. The bank’s strategic approach and operational focus have led to these favorable outcomes. Earnings Overview The net income for the...

Continue Reading
Birchtech Corp. Announces Third Quarter Earnings Call Details

Updated Category News Views 149

Birchtech Corp. Announces Third Quarter Earnings Call Details Birchtech Corp. (TSX:BCHT) (OTCQB:BCHT) is making waves in the specialty activated carbon industry. As a recognized leader in technologies for sustainable air and water treatment, this Texas-based company is gearing up for its third-quarter earnings call, scheduled for 5:00 p.m. Eastern Time on a Thursday in...

Continue Reading
Syntec Optics Enhances Product Lines for Next Generation Markets

Updated Category News Views 251

Syntec Optics Promotes Growth in the Satellite Sector Syntec Optics Holdings, Inc. (Nasdaq: OPTX), based in Rochester, New York, is making significant strides in the expanding space market. The company is not just a leader in advanced technology, defense, biomedical, and communications equipment but is now pivoting towards a profound expansion of its space products...

Continue Reading
Laura Celeste Updegraff: Trailblazer in Military Leadership and HR

Updated Category News Views 248

Celebrating Leadership and Achievement Laura Celeste Updegraff, MBA, MS, stands out as a magnificent figure in leadership, recognized within The Inner Circle as a Pinnacle Professional Member Inner Circle of Excellence. Her remarkable journey highlights a deep commitment to service in the U.S. Army and a strong dedication to human resources leadership. A Distinguished...

Continue Reading